239 related articles for article (PubMed ID: 11096349)
1. Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: a brief overview.
Terakawa N
Oncology; 2000; 59 Suppl 1():3-4. PubMed ID: 11096349
[No Abstract] [Full Text] [Related]
2. Playing the old piano: another tune for endocrine therapy?
Hayes DF
J Natl Cancer Inst; 2003 Nov; 95(21):1565-7. PubMed ID: 14600082
[No Abstract] [Full Text] [Related]
3. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
4. Re: Playing the old piano: another tune for endocrine therapy.
Koeberle D; Perey L; Thuerlimann B;
J Natl Cancer Inst; 2004 Apr; 96(7):555-6; author reply 556-7. PubMed ID: 15069120
[No Abstract] [Full Text] [Related]
5. Tamoxifen prevention of breast cancer: an instance of the fingerpost.
Lippman SM; Brown PH
J Natl Cancer Inst; 1999 Nov; 91(21):1809-19. PubMed ID: 10547388
[No Abstract] [Full Text] [Related]
6. How is tamoxifen's action subverted?
Jordan VC
J Natl Cancer Inst; 2000 Jan; 92(2):92-4. PubMed ID: 10639501
[No Abstract] [Full Text] [Related]
7. Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma.
Lamb CA; Helguero LA; Fabris V; Lucas C; Molinolo AA; Lanari C
Breast Cancer Res Treat; 2003 May; 79(1):25-35. PubMed ID: 12779079
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention of breast cancer.
O'Regan RM; Jordan VC
Cancer Treat Res; 2001; 106():137-54. PubMed ID: 11225001
[No Abstract] [Full Text] [Related]
9. Searching for an ideal SERM: Mining tamoxifen structure-activity relationships.
Price S; Bender SG; Yahn R; Till NA; Varady S; LaLonde RL
Bioorg Med Chem Lett; 2021 Nov; 52():128383. PubMed ID: 34592434
[TBL] [Abstract][Full Text] [Related]
10. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
11. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
Carroll JS; Lynch DK; Swarbrick A; Renoir JM; Sarcevic B; Daly RJ; Musgrove EA; Sutherland RL
Cancer Res; 2003 Aug; 63(15):4322-6. PubMed ID: 12907598
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
Obrero M; Yu DV; Shapiro DJ
J Biol Chem; 2002 Nov; 277(47):45695-703. PubMed ID: 12244117
[TBL] [Abstract][Full Text] [Related]
13. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
Reiter R; Oh AS; Wellstein A; Riegel AT
Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
[TBL] [Abstract][Full Text] [Related]
14. Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin.
Gielen SC; Burger CW; Kühne LC; Hanifi-Moghaddam P; Blok LJ
J Soc Gynecol Investig; 2005 Oct; 12(7):e55-67. PubMed ID: 16202921
[TBL] [Abstract][Full Text] [Related]
15. In search of the perfect SERM: beyond tamoxifen and raloxifene.
McNeil C
J Natl Cancer Inst; 1998 Jul; 90(13):956-7. PubMed ID: 9665139
[No Abstract] [Full Text] [Related]
16. Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells.
Eisen SF; Brown HA
Mol Pharmacol; 2002 Oct; 62(4):911-20. PubMed ID: 12237338
[TBL] [Abstract][Full Text] [Related]
17. [Hormone therapy and breast cancer].
de Cremoux P
Bull Cancer; 2011 Nov; 98(11):1311-9. PubMed ID: 22020743
[TBL] [Abstract][Full Text] [Related]
18. Modern antioestrogens and the coming revolution in women's health care.
Evans A; Vollenhoven B; Healy D
Aust N Z J Obstet Gynaecol; 1999 Aug; 39(3):334-40. PubMed ID: 10554946
[TBL] [Abstract][Full Text] [Related]
19. Current status of selective estrogen receptor modulators (SERMs).
Conzen SD
Cancer J; 2003; 9(1):4-14. PubMed ID: 12602762
[No Abstract] [Full Text] [Related]
20. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
Peng J; Sengupta S; Jordan VC
Anticancer Agents Med Chem; 2009 Jun; 9(5):481-99. PubMed ID: 19519291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]